Utility of Emphasis-10 in PAH Risk Stratification
Research type
Research Study
Full title
Utility of the EmPHasis-10 patient questionnaire in Risk Stratification in Pulmonary Arterial Hypertension
IRAS ID
254446
Contact name
Robin Condliffe
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 5 months, 1 days
Research summary
Pulmonary arterial hypertension (PAH) is a life-threatening condition characterised by remodelling of blood vessels and increased pressure in the blood vessels of the lungs, ultimately leading to right heart failure. Symptoms include exercise limitation, breathlessness and leg swelling. PAH also affects quality of life which can be quantitatively assessed using patient questionnaires, including the “EmPHasis-10” questionnaire. The E-10 questionnaire can be completed by a patient in a few minutes and produces a “score” of between 0-50.
The World Health Organization Functional Class system (WHO FC) is used to describe how ill patients with pulmonary hypertension are. The WHO FC system uses the classes I, II, III and IV which are assigned by a healthcare professional. The higher the class the more severe the disease.
Risk stratification is used in the management of patients with PAH and aims to identify patients at higher and lower risk of deterioration, so that the right treatments can be started in patients more quickly, and/or patients can be referred for heart/lung transplantation.
Three recent studies have demonstrated that Risk Stratification approaches using a measure of exercise capacity (the 6 minute walk test), right heart function (using a blood test for a biomarker called NT-pro BNP) and WHO Functional Class can stratify patients into groups at low, medium and high risk of deterioration.
The proposed multi-centre study aims to compare the EmPHasis-10 questionnaire against the WHO Functional Class system, in prognostic utility (that is, how well each assessment will predict the course of disease in patients with pulmonary arterial hypertension) and thus risk stratification.
The study will use de-identified data that has been previously collected as part of routine care of a large cohort of patients with PAH from a number of hospitals with PH Centres around the UK.
REC name
N/A
REC reference
N/A